Department of Radiotherapy, ICANS, Institut Cancérologie Strasbourg Europe, 17 rue Albert Calmette, 67200, Strasbourg Cedex, France.
Department of Radiology, Amiens-Picardie University Hospital, 1 rond-point du Professeur Christian Cabrol, 80054, Amiens Cedex 1, France.
Crit Rev Oncol Hematol. 2021 Mar;159:103230. doi: 10.1016/j.critrevonc.2021.103230. Epub 2021 Jan 27.
After chemoradiotherapy for glioblastoma, pseudoprogression can occur and must be distinguished from true progression to correctly manage glioblastoma treatment and follow-up. Conventional treatment response assessment is evaluated via conventional MRI (contrast-enhanced T1-weighted and T2/FLAIR), which is unreliable. The emergence of advanced MRI techniques, MR spectroscopy, and PET tracers has improved pseudoprogression diagnostic accuracy. This review presents a literature review of the different imaging techniques and potential imaging biomarkers to differentiate pseudoprogression from true progression.
在胶质母细胞瘤的放化疗后，可能会出现假性进展，必须将其与真性进展区分开来，以正确管理胶质母细胞瘤的治疗和随访。传统的治疗反应评估是通过常规 MRI（增强 T1 加权和 T2/FLAIR）进行的，但这种方法不可靠。先进的 MRI 技术、磁共振波谱和 PET 示踪剂的出现提高了假性进展的诊断准确性。本文对不同的成像技术和潜在的成像生物标志物进行了综述，以区分假性进展和真性进展。
